TrialBlood advances2022

Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study.

Walter Ageno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.